Last Updated: November 16, 2026

Details for Patent: 10,842,777

« Back to Dashboard


Which drugs does patent 10,842,777 protect, and when does it expire?

Patent 10,842,777 protects ATTRUBY and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.

Summary for Patent: 10,842,777
Title:Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
Abstract:Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.
Inventor(s):Isabella A. Graef, Mamoun M. Alhamadsheh
Assignee: Leland Stanford Junior University
Application Number:US16/510,574
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 10,842,777: Claim Scope, TTR Stabilizer Coverage, and Patent Landscape

U.S. Patent No. 10,842,777 protects three related method categories involving a defined Compound VIIa genus: TTR stabilization, reduction of amyloid fibril formation, and labeled-compound assays for detecting or quantifying transthyretin. The claims are composition-specific through the Compound VIIa structure and substituent Ra, but method-limited rather than directed to the compound as a standalone composition.

The strongest commercial risk is for products that use Compound VIIc, or a pharmaceutically acceptable salt of Compound VIIc, in TTR-stabilization or amyloid-formation assays. The patent does not, based on the supplied claims, broadly cover every TTR stabilizer, every amyloid-treatment method, or every diagnostic assay involving TTR.

What does U.S. Patent 10,842,777 cover?

The patent contains three independent claim concepts:

Claim group Independent claim Protected activity Primary commercial relevance
TTR stabilization Claim 1 Contacting tissue or biological fluid with Compound VIIa Research reagents, ex vivo stabilization, therapeutic methods depending on specification and prosecution history
Amyloid fibril reduction Claim 4 Contacting tissue or biological fluid with Compound VIIa to reduce fibril formation TTR amyloidosis research and therapeutic-use activities
TTR detection or quantification Claim 7 Using labeled Compound VIIa and distance-dependent energy transfer to measure TTR Diagnostic assays, binding assays, screening platforms and FRET-type tests

Claims 2, 3, 5, 6, 8 and 9 narrow the independent claims by limiting the Ra substituent or requiring Compound VIIc.

The patent therefore has a split claim strategy:

  1. A functional method for stabilizing TTR.
  2. A functional method for inhibiting or reducing amyloid fibril formation.
  3. A technically narrower analytical method using labeled Compound VIIa and an orthogonal TTR binding surface.

What chemical genus does Compound VIIa cover?

Ra substituent scope

Claims 1, 4 and 7 define Compound VIIa by permitting Ra to be:

  • OH
  • CHO
  • COOH
  • CONH2
  • CONH(OH)
  • COOR6
  • CONHR6

R6 is straight- or branched-chain alkyl containing one to three carbon atoms.

The R6 options include methyl, ethyl, n-propyl and isopropyl groups, subject to the claim language and the structure shown in the patent. Claims 2, 5 and 8 remove the OH and CHO alternatives and retain the more polar carboxylic acid, amide, hydroxamic acid, ester and alkylamide substituents.

This creates two practical tiers:

Claim tier Ra coverage Scope assessment
Broad genus OH, CHO, COOH, CONH2, CONH(OH), COOR6, CONHR6 Broadest literal coverage within Compound VIIa
Narrower genus COOH, CONH2, CONH(OH), COOR6, CONHR6 Excludes phenolic and aldehyde variants
Species claims Compound VIIc Narrower, potentially stronger against a specifically identified product

The exact chemical boundaries depend on the structural drawings and specification definitions for Compound VIIa and VIIc. The text supplied does not reproduce those structures. As a result, the exact molecular identity of Compound VIIc cannot be determined from the claim text alone.

What does the pharmaceutically acceptable salt language add?

The phrase "or a pharmaceutically acceptable salt thereof" extends the claims beyond the neutral form of the claimed compound. Depending on the compound’s ionizable groups, this may cover salts formed at a carboxylic acid or other relevant functional group.

The salt language is important for commercial products because a development candidate may be formulated as a sodium, potassium, calcium, meglumine, lysine or other salt without changing the core active moiety. Infringement would turn on whether the salt is within the claim and whether the accused activity practices every method limitation.

The claims do not expressly recite:

  • A particular dosage;
  • A particular route of administration;
  • A specific patient population;
  • A particular formulation;
  • A treatment duration;
  • A TTR mutation;
  • A defined tissue source;
  • A specific buffer or solvent;
  • A particular pharmaceutical excipient.

Those omissions make the claims potentially broad as methods, but they also create validity and infringement issues concerning enablement, written description, claim construction and the meaning of "contacting."

How do claims 1 through 6 protect TTR stabilization and amyloid reduction?

Claim 1: TTR stabilization

Claim 1 requires:

  1. A tissue or biological fluid;
  2. Contact with that tissue or fluid;
  3. Compound VIIa within the specified Ra genus or a pharmaceutically acceptable salt.

The claim does not require a particular measured stabilization endpoint. The supplied text also does not require that TTR remain tetrameric for a stated period or that a specific assay be used.

Potentially relevant activities include:

  • Ex vivo stabilization of TTR-containing plasma or serum;
  • Laboratory screening of TTR ligands;
  • Stabilization of recombinant TTR;
  • Testing of TTR variants;
  • Use of the compound in tissue-based amyloid assays;
  • Therapeutic administration, if the specification and prosecution history support interpreting "contacting" to include in vivo administration.

The absence of a patient or disease limitation gives claim 1 broader potential reach than a conventional treatment claim. Its weakness is that the claim may depend heavily on how the court interprets the physical act of "contacting" and the required proof of TTR stabilization.

Claim 2: narrowed Ra group

Claim 2 excludes the OH and CHO embodiments. A product using a carboxylic acid, amide, hydroxamic acid, ester or short-chain alkylamide remains within the literal scope if the rest of Compound VIIa is unchanged.

Claim 3: Compound VIIc species

Claim 3 narrows claim 1 to Compound VIIc or a pharmaceutically acceptable salt. A specifically identified clinical or research compound may therefore face greater risk under claim 3 than under the broader genus if it is structurally identical to VIIc.

Claim 4: reduction of amyloid fibril formation

Claim 4 uses the same Compound VIIa genus but changes the functional result from TTR stabilization to decreasing amyloid fibril formation.

This creates separate infringement exposure. A defendant could avoid a claim 1 theory by disputing whether its product stabilizes TTR, but still face claim 4 if its product is shown to reduce fibril formation in the relevant tissue or fluid.

The claim does not expressly limit fibrils to TTR-derived fibrils in the text supplied. The surrounding specification, however, is likely important because the claim is tied to TTR chemistry and Compound VIIa. The scope should not automatically be read as covering fibrils from unrelated proteins.

Claims 5 and 6

Claims 5 and 6 repeat the narrower Ra group and Compound VIIc limitation for claim 4. They provide fallback positions if the broader genus claims are challenged.

What does claim 7 protect in TTR diagnostic testing?

Claim 7 is technically distinct from claims 1 and 4. It requires:

  1. A sample containing biological fluid or tissue;
  2. Addition of labeled Compound VIIa;
  3. Binding of the labeled compound to TTR;
  4. Measurement of distance-dependent energy transfer;
  5. Energy transfer involving the labeled Compound VIIa at a T4 binding pocket and another labeled compound, peptide or protein at an orthogonal binding surface on the TTR tetramer.

This is a binding-proximity assay. The claim appears directed to a FRET-like or related energy-transfer method in which two binding events report on the conformation, assembly or occupancy state of the TTR tetramer.

What is the significance of the orthogonal binding surface?

TTR has thyroxine-binding pockets and additional ligand or antibody interaction surfaces. Claim 7 requires the second labeled species to bind at an orthogonal surface rather than simply measuring signal from the T4 pocket alone.

That limitation may distinguish the claimed assay from:

  • Direct ligand-binding assays;
  • Surface plasmon resonance;
  • Mass spectrometry;
  • Unlabeled immunoassays;
  • Single-fluorophore assays;
  • Generic TTR concentration tests;
  • Assays that do not use a second labeled binding partner.

The claim may cover measurement of TTR concentration, conformational state, ligand occupancy or tetramer assembly if the required energy-transfer relationship is present. It does not necessarily cover a diagnostic kit unless the kit is used in the claimed method.

Claims 8 and 9

Claim 8 narrows claim 7 to the carboxylic acid, amide, hydroxamic acid, ester and short-chain alkylamide Ra group.

Claim 9 narrows claim 7 to Compound VIIc. This is likely the most commercially relevant diagnostic claim if VIIc is used as the labeled T4-pocket ligand.

How many patents cover Compound VIIa and Compound VIIc?

The supplied material establishes one patent, U.S. Patent No. 10,842,777. It does not establish the full patent family, continuation applications, foreign counterparts, terminal disclaimers, reexaminations or later patents claiming the same compounds.

For freedom-to-operate purposes, the relevant estate should be separated into five categories:

Estate category Relevance to Compound VIIa/VIIc
Composition-of-matter patents Highest risk if the compound itself is claimed
Salt and crystalline-form patents Relevant to commercial active forms
Formulation patents Relevant to tablets, capsules, liquid formulations and stability systems
Method-of-treatment patents Relevant to use in TTR amyloidosis and related diseases
Diagnostic and assay patents Directly relevant to claim 7 and laboratory use

U.S. Patent 10,842,777, based on the supplied claims, is principally a method patent. It does not show a standalone composition claim to Compound VIIa or VIIc. A product could therefore avoid the patent only if it does not practice the claimed methods, even if the underlying compound is chemically similar. That conclusion cannot be extended to other family members without reviewing the related applications.

When does U.S. Patent 10,842,777 lose exclusivity?

The patent issued on November 24, 2020. Its effective expiration depends on the earliest effective nonprovisional filing date, any patent-term adjustment, patent-term extension and terminal disclaimer. Patent term is generally measured from the earliest effective U.S. nonprovisional filing date for the relevant family, not from the issue date.[1]

The supplied claim text does not establish the priority chain or the final term-adjustment calculation. The issue date alone is insufficient to state a legally reliable expiration date. Any commercial exclusivity analysis should use the USPTO patent record and the patent face data rather than infer expiration from the grant date.

The patent is not, based on the claims provided, an Orange Book product patent. Orange Book listing requires an approved drug product and a patent that meets FDA listing rules. A research-use method patent ordinarily does not create Orange Book-listed exclusivity by itself.[2]

What is the FDA and Orange Book status?

The claims do not establish FDA approval of Compound VIIa or Compound VIIc. They also do not identify a New Drug Application, biologics license application, approved dosage form or approved indication.

The likely regulatory classifications are:

Regulatory question Assessment from supplied claims
FDA-approved drug identified? No
Approved active ingredient identified? No
Orange Book product listed? Not established
Approved diagnostic using claim 7? Not established
Biosimilar pathway relevant? No, unless the product is a biologic, which these claims do not indicate
Generic pathway relevant? Potentially, only if a matching approved small-molecule product exists

A small-molecule product would ordinarily face an abbreviated new drug application pathway only after an FDA reference product exists and the proposed product satisfies the applicable sameness and bioequivalence requirements. The patent itself does not create a generic-drug pathway.

What generic-entry risks exist?

Small-molecule generic risk

Generic risk depends on whether Compound VIIa or VIIc has been approved as an active pharmaceutical ingredient and whether the patent is listed against that product. If no approved product exists, there is no conventional ANDA-based entry event tied to this patent.

If a matching product later receives approval, a Paragraph IV certification could challenge listed patent claims. Claims 1 and 4 could be relevant to use-based certification only if the approved label encourages the claimed stabilization or fibril-reduction method. Claim 7 would be more likely to affect a diagnostic product or research platform than an oral therapeutic.

Skinny-label and induced-infringement issues

A generic applicant could seek a label that omits a patented use. That strategy would be less effective if the approved label, promotional activity or clinical use necessarily directs physicians to practice TTR stabilization or amyloid-fibril reduction.

Claims 1 and 4 do not recite a specific disease. That may complicate a skinny-label strategy if the patented method is inseparable from the product’s principal use. The outcome would depend on the approved label and claim construction.

Biosimilar risk

Biosimilar risk is low on the present record. The patent claims small-molecule-style defined compounds and assay methods, not an antibody, recombinant protein or other biologic. A biosimilar applicant would not ordinarily challenge this patent merely because the reference product affects TTR.

What formulation and manufacturing protection exists?

No formulation or manufacturing claims appear in the nine claims supplied. The claims do not expressly cover:

  • Tablet or capsule compositions;
  • Amorphous or crystalline forms;
  • Polymorphs;
  • Particle-size distributions;
  • Solid dispersions;
  • Controlled-release systems;
  • Salt-selection processes;
  • Chemical synthesis steps;
  • Intermediates;
  • Purification methods;
  • Packaging or storage conditions.

That does not prove that the broader patent family lacks such protection. It means that the identified claims provide no direct formulation or manufacturing barrier.

A commercial developer should distinguish the method claims from possible follow-on rights covering the selected salt, polymorph, formulation or manufacturing route. Such follow-on patents often control practical launch timing even when the original method patent is weak.

Which companies are challenging the patent?

The supplied patent claims do not identify a Paragraph IV challenger, inter partes review petitioner, district-court defendant, settlement agreement or licensee. No litigation or licensing conclusion can be drawn from the claims alone.

The commercial competitor set for TTR stabilizers includes:

Product or program Company or sponsor Relevance
Tafamidis Pfizer Established TTR stabilizer and comparator
Acoramidis, formerly AG10 BridgeBio/Eidos TTR stabilizer designed to mimic protective T119M TTR behavior
Vutrisiran Alnylam TTR production-silencing therapy, not a stabilizer
Patisiran Alnylam TTR production-silencing therapy
Inotersen Ionis/AstraZeneca TTR production-silencing therapy
Eplontersen Ionis/AstraZeneca TTR production-silencing therapy

Tafamidis, acoramidis and RNA-silencing products compete clinically but do not create identical patent risks. Stabilizers target the TTR tetramer, while RNA-silencing agents reduce TTR production. Their patent estates therefore differ in claim type, regulatory pathway and manufacturing technology.

How strong is the patent estate?

Strengths

  • Claims cover both stabilization and amyloid-fibril reduction.
  • Compound VIIc species claims provide a narrower fallback position.
  • The claims reach biological fluids and tissues, not only purified laboratory protein.
  • Claim 7 targets a specialized assay architecture involving two binding surfaces and distance-dependent energy transfer.
  • Salt coverage may reach commercial pharmaceutical forms.

Vulnerabilities

  • The supplied claims do not include composition-of-matter protection.
  • "Contacting" may create claim-construction disputes for systemic administration and in vivo use.
  • The stabilization and fibril-reduction claims require proof of the claimed functional result.
  • Claim 7 requires several technical elements that may be absent from ordinary TTR assays.
  • Exact Compound VIIc identity cannot be evaluated without the structural drawing.
  • The patent’s commercial value depends heavily on whether the claimed compound is an approved or clinically relevant product.

Overall, the patent appears stronger as a targeted research and assay patent than as a complete commercial product barrier. Its highest value would arise if Compound VIIc is the active or analytical form used in a marketed TTR program and if related family members add composition, formulation or treatment claims.

Key Takeaways

  • U.S. Patent 10,842,777 covers methods using Compound VIIa or its salts to stabilize TTR, reduce amyloid fibril formation and measure TTR through a dual-label energy-transfer assay.
  • Claims 3, 6 and 9 narrow the protection to Compound VIIc.
  • Claims 2, 5 and 8 narrow the Ra group by excluding OH and CHO.
  • The patent claims methods, not a standalone Compound VIIa composition, based on the supplied claim set.
  • No formulation, synthesis or manufacturing claim appears in the nine claims provided.
  • Orange Book status, Paragraph IV activity, litigation, licensing and settlement status are not established by the claim text.
  • Biosimilar risk is low because the claims concern defined small-molecule-style compounds and diagnostic methods.
  • Generic risk depends on whether a product containing Compound VIIa or VIIc is approved and whether this patent is listed against that product.
  • The exact expiration date requires the patent’s priority chain, patent-term adjustment and any terminal disclaimer data.
  • Compound VIIc cannot be chemically identified from the supplied text because its structural drawing is absent.

FAQs

Does U.S. Patent 10,842,777 claim tafamidis?

The supplied claims do not identify tafamidis by name or establish that Compound VIIa or VIIc is tafamidis. Chemical identity must be confirmed from the patent’s structural drawings and specification.

Can a diagnostic laboratory infringe claim 7?

Potentially. A laboratory method may fall within claim 7 if it uses labeled Compound VIIa, binds it to the T4 pocket, uses a second labeled compound, peptide or protein at an orthogonal TTR surface, and measures distance-dependent energy transfer.

Does the patent cover all TTR amyloidosis treatments?

No. The supplied claims are limited to methods using Compound VIIa or its defined species. They do not cover unrelated TTR stabilizers, RNA-silencing drugs or antibody therapies.

Is a salt of Compound VIIc covered?

Yes, claim 3, claim 6 or claim 9 expressly includes a pharmaceutically acceptable salt of Compound VIIc, provided the other claim limitations are satisfied.

Can a product avoid the patent by using a different Ra substituent?

Possibly, but only if the alternative structure falls outside the full Compound VIIa definition and does not otherwise meet the relevant claim. A different Ra group alone may not avoid infringement if it remains within the claimed genus or if a related patent contains broader composition or method claims.

References

  1. United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation guidance. https://www.uspto.gov/patents/laws/patent-term-adjustment
  2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  3. United States Patent and Trademark Office. (2020). U.S. Patent No. 10,842,777.
  4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
  5. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,842,777

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes 10,842,777 ⤷  Start Trial TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,842,777

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2934514 ⤷  Start Trial 301323 Netherlands ⤷  Start Trial
European Patent Office 2934514 ⤷  Start Trial C20250016 Finland ⤷  Start Trial
European Patent Office 2934514 ⤷  Start Trial CA 2025 00013 Denmark ⤷  Start Trial
European Patent Office 2934514 ⤷  Start Trial PA2025512 Lithuania ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.